Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27461755 | 0.85 | GAA (0.60) | GAAMAPTHTR5A | |
| SCHEMBL27303285 | 0.85 | GAA (0.60) | GAAMAPTHTR5A | |
| SCHEMBL7144285 | 0.84 | GAA (0.42) | GAAMAPTHTR5ADPP9DPP4 | |
| SCHEMBL1760636 | 0.81 | SIRT1 (0.44) | GAAMAPTHTR5A | |
| SCHEMBL14081694 | 0.80 | GAA (0.40) | GAAMAPTDPP9DPP4DPP8 | |
| SCHEMBL926189 | 0.80 | GAA (0.40) | GAAMAPT | |
| SCHEMBL12641855 | 0.78 | DPP4 (0.52) | GAAMAPTPARP1DPP9DPP4 | |
| SCHEMBL1760501 | 0.77 | HSD17B10 (0.44) | GAAMAPTDPP4SCN3A | |
| SCHEMBL3257026 | 0.77 | ALDH1A1 (0.42) | GAAMAPT | |
| SCHEMBL12641805 | 0.77 | DPP4 (0.51) | GAAMAPTPARP1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247432-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-21 | — | — | US | disclosed |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY JOSEPH | 2011-09-15 | — | — | US | disclosed |
| US-7947713-B2 | (3-(4-phenyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydro-isoquinoline; inactivation of endogenous neuropeptides such as cholecystokinis; eating disorders, obesity, psychotic syndromes and associated psychiatric disorders; chemical intermediates coupling | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY J | 2008-05-08 | — | — | US | disclosed |
| WO-2008016811-A2 | AMINOPIPERIDINES AND REALTED COMPOUNDS | NEUROGEN CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1392291-B1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-30 | — | — | EP | disclosed |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | BRESLIN HENRY J | 2006-12-07 | — | — | US | disclosed |
| US-7125891-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-24 | — | — | US | disclosed |
| EP-1392291-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-03 | — | — | EP | disclosed |
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| WO-2002036116-A9 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002036116-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | GAA 1598/4885MAPT 4884/4885HTR5A 843/4885 |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | GAA 2335/4885MAPT 4881/4885HTR5A 201/4885 |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | GAA 2335/4885MAPT 4881/4885HTR5A 201/4885 |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | GAA 2335/4885MAPT 4881/4885HTR5A 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.